Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1357
Shown on this page
12
Current sort
Recently updated
Campus scope
Penn Medicine (University of Pennsylvania), Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Penn Medicine (University of Pennsylvania), Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 97–108 of 1,357 matching trials with a site at Penn Medicine (University of Pennsylvania), Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study

NCT06419335
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn Disease, Healthy
Interventions
CoQ10
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma

NCT03757689
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Wide Excision and Sentinel Lymph Node (SLN) Biopsy
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 2Phase 3 Interventional

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

NCT06616584
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
413
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

NCT02998229
Status at this site: Recruiting
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Artisse™ Intrasaccular Device
Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
25
States / cities
Los Angeles, California • Englewood, Colorado • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional

Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 Phase

NCT07787039
Status at this site: Recruiting
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
STORC
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

NCT07587021
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1, PH1
Interventions
YOLT-203, Placebo
Genetic · Drug
Lead sponsor
YolTech Therapeutics Co., Ltd
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849
Status at this site: Not yet recruiting
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
INCA33890, Placebo, Bevacizumab, FOLFOX
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
75
States / cities
Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201
Site status not listed — check the official record
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VX-264
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

The Progressive Supranuclear Palsy Clinical Trial Platform

NCT07173803
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP)
Interventions
AADvac1, LM11A-31
Biological · Drug
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

NCT07324031
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
Interventions
Atala™ lead and EV-ICD Pulse Generator
Device
Lead sponsor
AtaCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
Status at this site: Recruiting
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
141
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 10:21 AM EDT

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists
ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of Pennsylvania at any site, browse by condition, or browse by U.S. city.